Receptor-mediated toxicity and implications for risk assessment.
Andersen
M E
ME
Duke University Medical Center, Durham, North Carolina 27710.
Mills
J J
JJ
Fox
T R
TR
Goldsworthy
T L
TL
Conolly
R B
RB
Birnbaum
L S
LS
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003043:Cocarcinogenesis; D019388:Cytochrome P-450 CYP1A2; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004052:Diethylnitrosamine / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced; D008954:Models, Biological; D010088:Oxidoreductases / Q000378:metabolism; D010634:Phenobarbital / Q000633:toxicity; D000072317:Polychlorinated Dibenzodioxins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity*; D051381:Rats; D018336:Receptors, Aryl Hydrocarbon / Q000187:drug effects* / Q000502:physiology; D018570:Risk Assessment
D006133:Growth Substances; D000072317:Polychlorinated Dibenzodioxins; D018336:Receptors, Aryl Hydrocarbon; D004052:Diethylnitrosamine; D003577:Cytochrome P-450 Enzyme System; D010088:Oxidoreductases; D019388:Cytochrome P-450 CYP1A2; D010634:Phenobarbital